This week, new WHO data illustrates challenges during the acute phase of the COVID-19 pandemic, MAD-ID and ACVR conference coverage, and more from Contagion.
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
C difficile, Antimicrobials, and the Patients Most Affected
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients